Fig. 10From: Primary cold atmospheric plasma combined with low dose cisplatin as a possible adjuvant combination therapy for HNSCC cells—an in-vitro studyDetection of cell viability (%) with an MTT assay for all three cell types after cisplatin treatment. Mean and error bars 95% CI is shown for all three cell lines, (for each treatment time per cell type n = 15)Back to article page